ASS1 and mesothelioma: Thus, several mechanisms are apparent, namely, tumoral re‐expression of ASS1, stromal support via infiltrating macrophages identified in the earlier mesothelioma TRAP dose‐expansion cohort, and potentially drug‐dependent resistance, evidenced by an increasing titer of pegargiminase antibodies and a concomitant rise in arginine levels by week 16.17